Notably, no pharmacovigilance signal for hair disorders associated with anti-IL-5 biologics (mepolizumab, reslizumab, and benralizumab) was found, even though those have been reported in VigiBase. This evidence concerns the gene IL5 and disorder of pilosebaceous unit.